Back

Association between dapagliflozin, cardiac biomarkers, and cardiac remodeling in patients with diabetes mellitus and heart failure: a post-hoc analysis of a randomized study

25 August 2023 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Pathophysiology of heart failure: effects of interventions Ventricular Remodelling ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Andreas Xanthopoulos

University General Hospital of Larissa, Larissa (Greece)

6 More presentations in this session

Presentation thumbnail
Biomarker profiles of favorable ventricular remodeling in heart failure patients with reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial
Doctor J. Tromp (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Intravenous iron administration in patients with heart failure alters endothelial homeostasis with early release of endothelial microvesicles and subsequent mobilization of endothelial progenitor cell
Doctor S. Mause (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Effects of percutaneous coronary intervention on improvement of left ventricular ejection fraction among chronic coronary syndrome patients with left ventricular systolic dysfunction
Doctor L. Qiao (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Functional mitral regurgitation and ventricular arrhythmias in patients with cardiac resynchronization therapy
Doctor A. Yoshimura (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of cardiovascular polypharmacy on octogenarians with heart failure with preserved ejection fraction
Doctor M. Nishino (Sakai, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiology of heart failure: effects of interventions

The Event

Event poster

ESC Congress 2023

25 August 2023 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin's influence on cardiac remodeling in chronic heart failure patients
thumbnail
Congress Presentation
The impact of sodium glucose transporter 2 inhibitors on cardiac remodeling in a large cohort of unselected patients
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources